<i id='D87C639021'><strike id='D87C639021'><tt id='D87C639021'><pre id='D87C639021'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Guidelines to prevent youth baseball injuries need more muscle 
Reports of telehealth's death have been greatly exaggerated 
Medical records are filled with copy
Reports of telehealth's death have been greatly exaggerated 
Anesthesiologist group: stop taking Ozempic before surgery 
Bird flu surveillance in wastewater gets boost from consortium 
Peter Hotez and the public health issue of online harassment 
CMS should re 
FDA approval of Sarepta Duchenne genetic therapy gives me hope 
Questions and answers about ramping up H5N1 bird flu vaccine 
Moonlake's readout produced a cash windfall. Risks remain 
Why sickle cell disease is getting the first CRISPR treatment 
The cancer drug shortage isn’t new — and neither are the solutions 
Teach medical students about patients with intellectual disabilities 
Biden outlines 'new path' to provide student loan relief after Supreme Court rejection 
